Arboviruses have a tendency to co-circulate in similar geographical areas due to common epidemiological factors and vectors. Although each environment requires a different combination of vaccines to fully protect against infection, there is a great deal of overlap. This technology is a platform for multivalent vaccines that can be tailored to be region specific, safeguarding a patient against whatever combination of arboviruses are present. The technology combines several virus like particles (vlp’s) into a dimer, trimer, or tetrameric molecule, allowing vaccination against multiple viruses in a single deliverable. Advantages over traditional strategies include: a reduced number of individual or unnecessary vaccines given, vlp’s can be combined in many different ways to match geographic needs, and vlp’s are safer for pregnant and immunocompromised patients. Currently, vlp’s to Zika, Chikungunya, Japanese Encephalitis, and Yellow Fever have been developed for use in this platform.
-Virus-like particle production
Features, Benefits and Advantages
-Safe for pregnant women, children, and immunocompromised
-Tailorable, region specific combinations of vaccine in one treatment, a global vaccination system for soldiers abroad
-More immunogenic than viral proteins alone
-Efficient and simple production via stable cell lines
-Preliminary testing of vlp’s in mice.
-Himanshu Garg, Department of Biomedical Sciences, Center of Emphasis in Infectious Diseases, Texas Tech University Health Sciences Center, El Paso, TX.
-Anjali Joshi, Department of Biomedical Sciences, Center of Emphasis in Infectious Diseases, Texas Tech University Health Sciences Center, El Paso, TX.
Vaccine, multivalent, virus-like particle, arbovirus, zika, yellow fever, chikungunya, Japanese encephalitis